MA33725B1 - Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds - Google Patents

Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds

Info

Publication number
MA33725B1
MA33725B1 MA34835A MA34835A MA33725B1 MA 33725 B1 MA33725 B1 MA 33725B1 MA 34835 A MA34835 A MA 34835A MA 34835 A MA34835 A MA 34835A MA 33725 B1 MA33725 B1 MA 33725B1
Authority
MA
Morocco
Prior art keywords
compound
pgds
inhibitors
phenyloxadiazole
derivatives
Prior art date
Application number
MA34835A
Other languages
Arabic (ar)
English (en)
Inventor
Harpal S Gill
George Lee
Andrea Hillegass
Christopher L Vandeusen
Franz J Weiberth
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33725B1 publication Critical patent/MA33725B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Cette invention porte sur un composé de la formule (i) : dans laquelle r1, r2 et r3 sont tels que définis par les présentes, sur une composition pharmaceutique comportant le composé, sur des intermédiaires et sur des procédés de fabrication desdits composés, et sur l'utilisation du composé pour traiter des troubles allergiques et/ou inflammatoires, en particulier des troubles tels que la rhinite allergique, l'asthme, la broncho-pneumopathie obstructive chronique (copd) et la dégénérescence maculaire liée à l'âge (amd).
MA34835A 2009-10-08 2012-05-04 Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds MA33725B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24969309P 2009-10-08 2009-10-08
FR1056094 2010-07-26
PCT/US2010/051727 WO2011044307A1 (fr) 2009-10-08 2010-10-07 Dérivés de phényloxadiazole en tant qu'inhibiteurs de pgds

Publications (1)

Publication Number Publication Date
MA33725B1 true MA33725B1 (fr) 2012-11-01

Family

ID=43606440

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34835A MA33725B1 (fr) 2009-10-08 2012-05-04 Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds

Country Status (21)

Country Link
US (5) US9469627B2 (fr)
EP (1) EP2486024B1 (fr)
JP (2) JP5753176B2 (fr)
KR (1) KR101701135B1 (fr)
CN (3) CN102666508A (fr)
AR (1) AR078552A1 (fr)
AU (1) AU2010303439B2 (fr)
BR (1) BR112012007635B1 (fr)
CA (1) CA2776242C (fr)
DK (1) DK2486024T3 (fr)
ES (1) ES2543011T3 (fr)
HK (1) HK1173441A1 (fr)
IL (1) IL218967A (fr)
MA (1) MA33725B1 (fr)
MX (1) MX2012003021A (fr)
NZ (1) NZ599099A (fr)
RU (2) RU2572608C2 (fr)
SG (1) SG179199A1 (fr)
TW (1) TWI508960B (fr)
UY (1) UY32938A (fr)
WO (1) WO2011044307A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003021A (es) * 2009-10-08 2012-04-10 Sanofi Sa Derivados de feniloxadiazol como agentes inhibidores de las pgds.
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
KR20180095580A (ko) 2015-12-17 2018-08-27 아스텍스 테라퓨틱스 리미티드 H-pgds 억제제로서의 퀴놀린-3-카르복스아미드
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
WO2018215807A1 (fr) * 2017-05-22 2018-11-29 Egis Gyógyszergyár Zrt. Procédé de production d'ozanimod
BR112019026452A2 (pt) 2017-06-13 2020-07-14 Glaxosmithkline Intellectual Property Development Limited compostos químicos como inibidores de h-pgds
US20210139507A1 (en) 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
WO2020095215A1 (fr) 2018-11-08 2020-05-14 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
CA3183214A1 (fr) 2020-06-19 2021-12-23 Motoaki Baba Composes cycliques condenses qui inhibent la h-pgds
WO2023113023A1 (fr) 2021-12-17 2023-06-22 佐藤製薬株式会社 Dérivé d'azaindole inhibant h-pgds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DE10117823A1 (de) 2001-04-10 2002-10-17 Merck Patent Gmbh Oxalsäurederivate
WO2003078409A1 (fr) * 2002-03-19 2003-09-25 Ono Pharmaceutical Co., Ltd. Composes d'acide carboxylique et medicaments renfermant les composes comme principe actif
KR20050035885A (ko) 2002-08-16 2005-04-19 아벤티스 파마슈티칼스 인크. 마이크로솜성 프로스타글란딘 ｅ 신타제 또는 조혈성 프로스타글란딘 ｄ 신타제의 활성을 감소시키는 능력에 대해 화합물 또는 제제를 검정하는 방법
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
WO2005094805A1 (fr) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. Dérivé imine et dérivé amide
DE602005020127D1 (de) * 2004-04-21 2010-05-06 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
JP5209181B2 (ja) * 2005-03-15 2013-06-12 富士フイルム株式会社 化合物、組成物、位相差板、楕円偏光板および液晶表示装置
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
CN100556905C (zh) * 2005-09-08 2009-11-04 国家南方农药创制中心江苏基地 吡唑酰胺类化合物及其中间体和以该类化合物为活性成分的有害生物防治剂
WO2007039177A2 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
PE20070589A1 (es) 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
CA2672373C (fr) 2006-12-19 2011-08-30 Pfizer Products Inc. Derives de la nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation dans le traitement de maladies liees aux prostaglandines d2
JP2010519328A (ja) * 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用
CA2682629C (fr) 2007-03-30 2013-03-19 Sanofi-Aventis Composes d'hydrazide de pyrimidine en tant qu'inhibiteurs de pgds
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2010080653A1 (fr) 2009-01-12 2010-07-15 The Government Of U.S.A, As Represented By The Secretary Of The Navy Structure d'électrode composite
MX2012003021A (es) 2009-10-08 2012-04-10 Sanofi Sa Derivados de feniloxadiazol como agentes inhibidores de las pgds.

Also Published As

Publication number Publication date
EP2486024B1 (fr) 2015-04-22
US9937175B2 (en) 2018-04-10
BR112012007635A2 (pt) 2017-06-20
DK2486024T3 (en) 2015-07-27
AR078552A1 (es) 2011-11-16
US20190000845A1 (en) 2019-01-03
CN107875155A (zh) 2018-04-06
JP5897186B2 (ja) 2016-03-30
TWI508960B (zh) 2015-11-21
CA2776242C (fr) 2014-09-02
CN102666508A (zh) 2012-09-12
ES2543011T3 (es) 2015-08-13
IL218967A (en) 2015-05-31
JP2013507376A (ja) 2013-03-04
MX2012003021A (es) 2012-04-10
US20120190695A1 (en) 2012-07-26
HK1173441A1 (en) 2013-05-16
EP2486024A1 (fr) 2012-08-15
US20230190747A1 (en) 2023-06-22
BR112012007635B1 (pt) 2019-07-09
CN106943407A (zh) 2017-07-14
KR20120094910A (ko) 2012-08-27
UY32938A (es) 2011-05-31
RU2572608C2 (ru) 2016-01-20
RU2015151129A3 (fr) 2019-07-17
NZ599099A (en) 2013-05-31
SG179199A1 (en) 2012-04-27
RU2012118756A (ru) 2013-11-20
CA2776242A1 (fr) 2011-04-14
AU2010303439A1 (en) 2012-04-26
AU2010303439B2 (en) 2015-10-29
JP5753176B2 (ja) 2015-07-22
US20190262338A1 (en) 2019-08-29
US20170231990A1 (en) 2017-08-17
WO2011044307A1 (fr) 2011-04-14
IL218967A0 (en) 2012-07-31
TW201127835A (en) 2011-08-16
KR101701135B1 (ko) 2017-02-01
US9469627B2 (en) 2016-10-18
RU2015151129A (ru) 2019-01-15
JP2015178516A (ja) 2015-10-08

Similar Documents

Publication Publication Date Title
MA33725B1 (fr) Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds
MA31326B1 (fr) Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds
MA29925B1 (fr) Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds
NO20084005L (no) Aminderivater
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
TW200616620A (en) Compounds for the treatment of inflammatory disorders
MA35285B1 (fr) Indazoles
TW200612911A (en) Compounds for the treatment of inflammatory disorders
TW200738688A (en) Compounds for the treatment of inflammatory disorders
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
TW200736248A (en) Compounds for the treatment of inflammatory disorders
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MX2009013885A (es) Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico.
EA200701879A1 (ru) Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина
NO20090646L (no) Xinafoatsalt av en substituert 5-oksazol-2-yl-kinolinforbindelse
NO20092413L (no) Pyrazolanaloger
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
UA95861C2 (en) Glucocorticoid receptor agonists
TH105528A (th) สารประกอบไพริมิดีน เอไมด์ ที่เป็นสารยับยั้งพรอสตาแกลนดิน
NO20064805L (no) Sammensetninger for behandling av sykdommer
MA28302A1 (fr) Derives de sulfonamides pour le traitement de maladies
TH105899B (th) สารประกอบใหม่
TN2010000612A1 (fr) Derives de triazole utiles pour le traitement de maladie
TH87151B (th) สารประกอบเคมี